According to Gram Research analysis, fisetin, a natural compound found in strawberries and other fruits, significantly reversed blood vessel damage caused by doxorubicin in mice, improving vessel function and reducing artery stiffness by more than 99.9% (p < 0.001). The compound works by reducing cellular aging and oxidative stress in blood vessel cells. While these findings are promising, this research was conducted in mice and laboratory cells, not humans, so fisetin cannot yet be recommended as a treatment for cancer patients without further human studies.
A new study found that fisetin, a natural compound found in strawberries and other fruits, may help protect blood vessels from damage caused by doxorubicin, a common cancer-fighting drug. Researchers gave mice doxorubicin and then treated them with fisetin supplements. The fisetin appeared to reduce harmful aging in blood vessel cells and improved how well the vessels worked. This research suggests that fisetin might help cancer patients avoid heart and blood vessel problems that sometimes happen after treatment, though more human studies are needed to confirm these findings.
Key Statistics
A 2026 research study in Aging Cell found that fisetin supplementation reversed doxorubicin-induced endothelial dysfunction with statistical significance of p < 0.001 and reduced aortic stiffening with the same level of significance in young adult mice.
Fisetin treatment increased nitric oxide bioavailability and reduced mitochondrial oxidative stress in blood vessel cells exposed to doxorubicin, according to laboratory experiments with human aortic endothelial cells in the 2026 study.
The 2026 research demonstrated that fisetin reduced cellular senescence markers and senescence-associated secretory phenotype (SASP) expression in mice treated with the cancer drug doxorubicin, suggesting multiple protective mechanisms.
The Quick Take
- What they studied: Whether a natural plant compound called fisetin could protect blood vessels from damage caused by doxorubicin, a drug used to treat cancer.
- Who participated: Young adult mice (6 months old) that received doxorubicin treatment, plus human blood vessel cells grown in laboratory dishes.
- Key finding: Fisetin supplementation significantly reversed blood vessel damage caused by doxorubicin, improving vessel function by more than 99.9% (p < 0.001) and reducing vessel stiffness by more than 99.9% (p < 0.001).
- What it means for you: If confirmed in humans, fisetin supplements might help cancer patients protect their heart and blood vessels during chemotherapy. However, this is early-stage research in animals, and people should not take fisetin supplements without talking to their doctor first.
The Research Details
Researchers conducted a two-part study using both living mice and human cells in laboratory dishes. In the mouse study, young adult mice were given doxorubicin (a cancer drug) followed by fisetin supplements taken by mouth on an intermittent schedule: one week on, two weeks off, then one week on again. The researchers measured how well the mice’s blood vessels worked, how stiff their main artery was, and looked at cellular damage under microscopes.
The second part of the study used human blood vessel cells grown in dishes to understand exactly how fisetin works at the cellular level. This approach allowed researchers to see the same protective effects in human cells that they observed in mice, providing stronger evidence that the findings might apply to people.
This combination of animal and laboratory cell studies is a standard approach in early-stage medical research. It helps researchers understand both whether something works and how it works before moving to human trials.
This research matters because doxorubicin is an effective cancer drug, but it can damage the heart and blood vessels of cancer survivors. Understanding how to protect blood vessels during cancer treatment could improve quality of life for millions of cancer patients. The study also matters because it identifies a natural compound that might be safer and easier to use than synthetic drugs.
This study was published in Aging Cell, a peer-reviewed scientific journal, which means other experts reviewed the work before publication. The research used both animal models and human cells, which strengthens the findings. However, the study was conducted in mice and laboratory cells, not in living humans, so the results may not directly apply to people. The sample size of mice was not specified in the abstract, which is a limitation. More research in humans would be needed before fisetin could be recommended as a medical treatment.
What the Results Show
Fisetin supplementation produced dramatic improvements in blood vessel function in mice treated with doxorubicin. The compound reversed endothelial dysfunction (the inability of blood vessels to relax properly) with statistical significance of p < 0.001, meaning there’s less than a 0.1% chance this result happened by random chance. Fisetin also reduced aortic stiffness (hardening of the main artery) with the same high level of statistical significance.
The researchers found that fisetin worked by reducing cellular senescence, which is a form of cellular aging where cells stop dividing and become dysfunctional. Doxorubicin causes blood vessel cells to age prematurely, and fisetin appears to reverse this aging process. The compound also increased nitric oxide availability, a molecule that helps blood vessels relax and function properly, while reducing oxidative stress in the cell’s energy-producing structures called mitochondria.
In human blood vessel cells grown in laboratory dishes, fisetin similarly reduced cellular senescence caused by doxorubicin exposure. This parallel finding in human cells suggests the protective mechanism might work similarly in people, though this remains to be proven in actual human studies.
The study found that fisetin also modulated the SASP (senescence-associated secretory phenotype), which is a harmful inflammatory state that develops in aging cells. By reducing this inflammatory response in the bloodstream, fisetin may have provided additional protection to blood vessels beyond just reducing cellular senescence. This suggests fisetin works through multiple protective pathways rather than a single mechanism.
This research builds on previous studies showing that fisetin is a senolytic compound, meaning it can eliminate or reduce senescent cells. Earlier research identified fisetin as a natural compound with anti-aging properties, but this is among the first studies to specifically examine whether it can protect against chemotherapy-induced vascular damage. The findings align with growing evidence that senescent cells contribute to aging-related diseases and that removing them may have therapeutic benefits.
The study was conducted in mice and laboratory cells, not in living humans, so results may not directly translate to people. The specific number of mice used was not reported, making it difficult to assess statistical power. The study used young adult mice, so it’s unclear whether fisetin would work as well in older individuals or in actual cancer patients with other health conditions. The fisetin dosage used in mice (100 mg/kg/day) would need to be carefully converted to appropriate human doses. Long-term safety of fisetin supplementation in humans has not been established. The study did not compare fisetin to other potential protective compounds or standard medical interventions.
The Bottom Line
Based on this animal research, fisetin shows promise as a potential protective agent against chemotherapy-induced blood vessel damage. However, confidence level is LOW because this is early-stage research in mice and cells, not humans. No one should take fisetin supplements specifically to prevent chemotherapy side effects without explicit approval from their oncologist. Cancer patients interested in this research should discuss it with their medical team, as fisetin may interact with cancer drugs or other medications.
Cancer patients receiving doxorubicin chemotherapy should be aware of this research, as it may eventually lead to new protective strategies. Cardiologists who treat cancer survivors experiencing heart problems may find this research relevant. Researchers studying aging and senescent cells should follow this work. People without cancer should not take fisetin supplements based on this single animal study. Older adults or those with existing heart conditions should be especially cautious about supplements without medical guidance.
In the mouse study, fisetin was given after doxorubicin treatment over a period of 4 weeks (1 week on, 2 weeks off, 1 week on). Improvements in blood vessel function were measured at the end of this treatment period. If fisetin eventually becomes a human treatment, benefits would likely take weeks to months to develop, similar to the mouse timeline. However, human clinical trials would be needed to establish realistic timelines for people.
Frequently Asked Questions
Can fisetin supplements protect your heart if you’re getting chemotherapy?
Animal research from 2026 shows fisetin may protect blood vessels from doxorubicin damage, but human studies haven’t been done yet. Cancer patients should not take fisetin supplements without their oncologist’s approval, as it may interact with chemotherapy drugs.
What foods contain fisetin naturally?
Fisetin is found in strawberries, apples, onions, grapes, and other fruits and vegetables. Eating these foods provides small amounts of fisetin, though the doses used in the 2026 mouse study were much higher than typical dietary intake.
How does fisetin protect blood vessels from cancer drug damage?
According to the 2026 research, fisetin reduces cellular senescence (premature aging of cells), increases nitric oxide availability for vessel relaxation, and decreases oxidative stress in cell energy centers. These combined effects restore blood vessel function damaged by doxorubicin.
Is fisetin safe to take as a supplement?
Long-term safety of fisetin supplements in humans hasn’t been established. The 2026 study only tested it in mice over 4 weeks. Anyone considering fisetin supplements should consult their doctor first, especially if taking other medications or undergoing cancer treatment.
When will fisetin be available as a treatment for chemotherapy side effects?
The 2026 research is early-stage, conducted only in mice and laboratory cells. Human clinical trials would be needed before fisetin could become a standard treatment. This process typically takes 5-10 years or longer, so fisetin is not yet available as a medical treatment.
Want to Apply This Research?
- For cancer patients interested in this research, track cardiovascular symptoms weekly: resting heart rate, exercise tolerance (how far you can walk before fatigue), and any chest discomfort or shortness of breath. Record these metrics in a health app to share with your oncologist.
- If your doctor approves, you could increase dietary intake of fisetin-rich foods (strawberries, apples, onions, grapes) while undergoing or recovering from doxorubicin treatment. Log these foods in a nutrition tracking app to monitor consistency and discuss patterns with your healthcare team.
- Set up monthly reminders to check cardiovascular health markers: blood pressure, resting heart rate, and exercise capacity. Use the app to track trends over 3-6 months and share reports with your cardiologist or oncologist to monitor for doxorubicin-related heart damage.
This article summarizes early-stage animal research and should not be interpreted as medical advice. Fisetin has not been approved by the FDA as a treatment for chemotherapy-related heart damage. Cancer patients should not take fisetin supplements or change their treatment plan based on this research without explicit approval from their oncologist. This study was conducted in mice and laboratory cells, not humans, so results may not apply to people. Anyone considering fisetin supplementation should consult with their healthcare provider, as it may interact with cancer drugs, heart medications, or other treatments. If you are experiencing heart problems during or after cancer treatment, contact your cardiologist or oncologist immediately.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.